Clinical Trial to Evaluate the Efficacy of Echinochrome A, An Active Principle of Sea Urchin Eggs, in Improving Quality of Life and Reducing Cellular Inflammation in Long Covid Patients

Introduction: The global impact of COVID-19 has resulted in a long COVID syndrome, which is defined by persistent symptoms and a significant decline in patients’ quality of life. To address this challenge, we conducted a multicenter, double-blind, randomized study to assess the effects of Echinochrome A, the active principle from sea urchin found in the dietary supplement Echa Marine®, on health-related quality of life and inflammatory biomarkers in 50 long-term COVID patients. Baseline characteristics were similar between groups. Methods: Adult men and non-pregnant women aged 18 to 60 diagnosed with long COVID were randomly assigned to the intervention or control groups. For three months, patients were given daily doses of EchA Marine®, a dietary supplement made from sea urchin eggs, or a matching placebo. The effects of EchA Marine® were assessed using the EuroQol 5-Dimension (EQ-5D) questionnaire and serum parameter measurements. Discussion: Consumers of EchA Marine®exhibited significant reductions in pain, improved mobility, enhanced overall quality of life, and improved inflammation biomarkers. These findings suggest that Echinochrome A, due to its antioxidant and anti-inflammatory properties, effectively alleviates long COVID symptoms, particularly pain and mobility. The results underscore the potential of EchA Marine® as a safe and natural remedy for long COVID patients, warranting further research with larger cohorts to consolidate its efficacy.